0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-1

B7-1

Brief Information

Name:Cluster of differentiation 80
Target Synonym:Activation B7-1 antigen,LAB7,T-lymphocyte activation antigen CD80,CD80 Molecule,CD80 Antigen (CD28 Antigen Ligand 1, B7-1 Antigen),B-Lymphocyte Activation Antigen B7,CTLA-4 Counter-Receptor B7.1,CD28LG1,BB1,Costimulatory Molecule Variant IgV-CD80,Costimul
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

B71-H52A4-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Human B7-1, Mouse IgG2a Fc Tag (Cat. No. B71-H52A4) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-1 is 1 μg/mL (Routinely tested).

B71-H52A4-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Human B7-1, Mouse IgG2a Fc Tag (Cat. No. B71-H52A4) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-human CTLA-4 antibody. The concentration of Human B7-1 is 1 μg /mL. The IC50 is 5.5 μg/mL (Routinely tested).

B71-H52A4-SPR
Human_FcRn_Heterodimer_Protein_SPR

Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, Mouse IgG2a Fc Tag (Cat. No. B71-H52A4) with an affinity constant of 2.72 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

CD0-M5259-SPR
Human_FcRn_Heterodimer_Protein_SPR

Mouse B7-1, Fc Tag (Cat. No. CD0-M5259) captured on CM5 chip via anti-human IgG Fc antibody can bind Mouse CD28, His Tag (Cat. No. CD8-M52H6) with an affinity constant of 49.6 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Customer Reviews

Synonym Name

CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7

Background

B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response.B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Belatacept LEA29Y; LEA-029; BMS-224818; L104EA29YIg Approved Bristol-Myers Squibb Company Nulojix EU Rejection of renal transplantation Bristol-Myers Squibb Pharma Eeig 2011-06-15 Rejection of renal transplantation; Rejection of organ transplantation Details
Abatacept BMS-188667; BMS-188667SC; ONO-4164SC; ONO-4164 Approved Bristol-Myers Squibb Company Orencia Mainland China Arthritis, Rheumatoid Bristol-Myers Squibb Company 2005-12-23 Nephrosis, Lipoid; Crohn Disease; Nephrotic Syndrome; Muscular Diseases; Colitis, Ulcerative; Arthritis, Psoriatic; Glomerulosclerosis, Focal Segmental; Psoriasis; Lupus Erythematosus, Systemic; Polymyositis; Multiple Sclerosis; Lupus Nephritis; Arthritis, Juvenile; Sjogren's Syndrome; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Dermatomyositis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Carcinoma, Non-Small-Cell Lung Details
rVV-740CTA vaccine (University Hospital Basel) rVV-740CTA Phase 1 Clinical University Hospital Basel Breast Neoplasms Details
Belatacept biosimilar (Alphamab) KN-019 Phase 2 Clinical Suzhou Alphamab Co Ltd Rejection of renal transplantation; Arthritis, Rheumatoid; Autoimmune Diseases Details

This web search service is supported by Google Inc.

totop